Overview

Study on Efficacy and Tolerability of Vorinostat in Patients With Advanced, Metastatic Soft Tissue Sarcoma (STS)

Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
Primary objective of the study is to investigate the efficacy of vorinostat in patients suffering from selected histological types of soft tissue sarcoma. Further evaluations relate to the safety and tolerability of vorinostat, its pharmacokinetics (course of plasma concentration over time) and pharmacodynamics (mode of action). Only subjects with advanced, metastatic disease will be included in this trail.
Phase:
Phase 2
Details
Lead Sponsor:
Heidelberg University
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Vorinostat